{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Participants with CR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}],"title":"Participants with PR"}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Overall response rate defined as Complete Response (CR), disappearance of all target lesions; or Partial Response (PR), at least a 30% decrease in sum of longest diameter (LD) of target lesions, taking as reference the baseline sum LD, assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Committee \\[JNCI 92(3):205-216, 2000\\]. In addition to a baseline scan, confirmatory scans for those deemed to have achieved a PR or CR.","groups":[{"description":"Intravenous Oxaliplatin 130 mg/m\\^2, Day 1 + Oral Capecitabine 750 mg/m\\^2 twice daily Days 1-14.","id":"OG000","title":"Oxaliplatin + Capecitabine"}],"paramType":"NUMBER","populationDescription":"Analysis was intent-to-treat; One patient developed an acute flare of Crohn's disease after one cycle of study treatment and was removed from study without undergoing restaging scans.","reportingStatus":"POSTED","timeFrame":"Every 9 weeks from treatment initiation and confirmatory images 6 weeks or more after initial responses","title":"Number of Participants With Overall Response","type":"PRIMARY","unitOfMeasure":"participants"}